Rapid pace of psychedelics development brings regulatory complexities
The Brown University Psychopharmacology Update November 1, 2026 DOI: 10.1002/pu.31507 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | The commentaries argue that rapid psychedelic drug development creates regulatory challenges, including approval conditions that could affect patient access and conflicts between federal and state policy; one author contends that public demand is outpacing federal regulatory guidance. |
Abstract
The rapid evolution of psychedelic drug development is creating numerous regulatory challenges, from potential conditions of approval that can affect patient access to differences in federal and state policy regarding the drugs, according to authors of two newly published commentaries. One of the authors emphasized that public demand for psychedelics is far outpacing federal regulatory guidance. The articles were published online July 15, 2026 in JAMA Psychiatry and June 18, 2026 in the New England Journal of Medicine .